Day One Biopharmaceuticals, Inc.
Commercial-stage company developing targeted cancer therapies, focusing on pediatrics.
DAWN | US
Overview
Corporate Details
- ISIN(s):
- US23954D1090
- LEI:
- Country:
- United States of America
- Address:
- 1800 SIERRA POINT PARKWAY, SUITE 200, 94005 BRISBANE
- Website:
- https://dayonebio.com/
- Sector:
- Manufacturing
Description
Day One Biopharmaceuticals is a commercial-stage company dedicated to developing and commercializing targeted therapies for people of all ages with cancer, with a particular focus on pediatric populations. The company's mission is to disrupt traditional drug development paradigms to accelerate the delivery of new medicines to patients with urgent needs. Employing a 'search and development' strategy, Day One identifies, acquires, and advances promising first- or best-in-class treatments. Its lead commercial product, tovorafenib, is a therapy developed for pediatric low-grade glioma (pLGG). The company collaborates with clinical oncologists, scientists, and patient communities to address unmet needs in both childhood and adult cancers with equal intensity.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Day One Biopharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Day One Biopharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Day One Biopharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
